HR12

Purpose

• Designates May 3–9, 2026 as Tardive Dyskinesia Awareness Week in Minnesota.
• Aims to raise awareness among the public and the medical community about tardive dyskinesia (TD), a movement disorder linked to certain long-term medications.
• Highlights the importance of recognizing and understanding TD for people taking dopamine receptor blocking agents (DRBAs), including antipsychotics, which are used to treat serious mental health conditions and some gastrointestinal disorders.

Main Provisions and Objectives

• Official designation: May 3–9, 2026 is set aside in Minnesota to focus attention on TD.
• Public and professional education: Encourages Minnesotans to become better informed about TD and its impact.
• Emphasis on screening and awareness: Draws attention to recommendations for regular TD screening in patients using DRBAs, as endorsed by the American Psychiatric Association.
• Acknowledgment of treatment options: Notes that there are two FDA-approved treatments for adults with TD, underscoring the importance of timely recognition and care.
• Scope of conditions affected: References TD in the context of serious mental health conditions (bipolar disorder, major depression, schizophrenia, schizoaffective disorder) and certain GI disorders (gastroparesis, nausea, vomiting) treated with DRBAs.

Context and Significance

• What TD is: TD is an involuntary movement disorder with symptoms such as uncontrollable movements of the face, torso, or other body parts.
• Why awareness matters: A large portion of TD cases are undiagnosed, and even mild symptoms can have physical, social, and emotional consequences.
• Relevance to treatment: Since DRBAs (including antipsychotics) are widely used, awareness and monitoring can help with early detection and access to approved treatments.

Relationship to Existing Law

• This is a non-binding resolution that designates a week for awareness and education.
• It does not create new legal requirements, funding, or statutory changes beyond the recognition of the awareness week.

Relevant Terms - tardive dyskinesia (TD) - TD awareness - tardive dyskinesia awareness week - dopamine receptor blocking agents (DRBAs) - antipsychotics - screening / monitoring for TD - American Psychiatric Association - U.S. Food and Drug Administration (FDA) - FDA-approved treatments for TD - bipolar disorder - major depressive disorder - schizophrenia - schizoaffective disorder - gastroparesis - nausea - vomiting - Minnesota - May 3–9, 2026